Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−10.15 M USD
0.00 USD
1.79 M
About Neuphoria Therapeutics Inc.
Sector
Industry
CEO
Spyridon Papapetropoulos
Website
Headquarters
Burlington
Founded
1996
FIGI
BBG01RFZ8658
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of NEUP is 6.78 USD — it has increased by 4.57% in the past 24 hours. Watch Neuphoria Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Neuphoria Therapeutics Inc. stocks are traded under the ticker NEUP.
NEUP stock has risen by 36.75% compared to the previous week, the month change is a 25.29% rise, over the last year Neuphoria Therapeutics Inc. has showed a −53.69% decrease.
We've gathered analysts' opinions on Neuphoria Therapeutics Inc. future price: according to them, NEUP price has a max estimate of 18.00 USD and a min estimate of 18.00 USD. Watch NEUP chart and read a more detailed Neuphoria Therapeutics Inc. stock forecast: see what analysts think of Neuphoria Therapeutics Inc. and suggest that you do with its stocks.
NEUP reached its all-time high on Dec 16, 2021 with the price of 264.00 USD, and its all-time low was 2.12 USD and was reached on Oct 28, 2024. View more price dynamics on NEUP chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
NEUP stock is 15.93% volatile and has beta coefficient of 2.70. Track Neuphoria Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is Neuphoria Therapeutics Inc. there?
Today Neuphoria Therapeutics Inc. has the market capitalization of 11.71 M, it has increased by 1.16% over the last week.
Yes, you can track Neuphoria Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Neuphoria Therapeutics Inc. is going to release the next earnings report on Aug 28, 2025. Keep track of upcoming events with our Earnings Calendar.
NEUP net income for the last quarter is 11.26 M USD, while the quarter before that showed −1.94 M USD of net income which accounts for 679.52% change. Track more Neuphoria Therapeutics Inc. financial stats to get the full picture.
No, NEUP doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 24, 2025, the company has 24 employees. See our rating of the largest employees — is Neuphoria Therapeutics Inc. on this list?
Like other stocks, NEUP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Neuphoria Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Neuphoria Therapeutics Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Neuphoria Therapeutics Inc. stock shows the buy signal. See more of Neuphoria Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.